Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Mieke A. Van Der Mescht"'
Autor:
Mieke A. van der Mescht, Helen C. Steel, Zelda de Beer, Andries Masenge, Fareed Abdullah, Veronica Ueckermann, Ronald Anderson, Theresa M. Rossouw
Publikováno v:
Microorganisms, Vol 12, Iss 11, p 2149 (2024)
Whether SARS-CoV-2 infection leads to a higher mortality and morbidity in people living with HIV (PLWH) in Africa remains inconclusive. In this study, we explored the differences in the T-cell phenotypes between people with and without HIV on the day
Externí odkaz:
https://doaj.org/article/b3d4d906a47942869fe2a701300d4203
Autor:
Mieke A. van der Mescht, Helen C. Steel, Zelda de Beer, Fareed Abdullah, Veronica Ueckermann, Ronald Anderson, Theresa M. Rossouw
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionSARS-CoV-2 elicits a hyper-inflammatory response that contributes to increased morbidity and mortality in patients with COVID-19. In the case of HIV infection, despite effective anti-retroviral therapy, people living with HIV (PLWH) exper
Externí odkaz:
https://doaj.org/article/438d62f709044eeba603b5ac7e8a821d
Autor:
Boitumelo M. Motsoeneng, Nelia P. Manamela, Haajira Kaldine, Prudence Kgagudi, Tandile Hermanus, Frances Ayres, Zanele Makhado, Thandeka Moyo-Gwete, Mieke A. van der Mescht, Fareed Abdullah, Michael T. Boswell, Veronica Ueckermann, Theresa M. Rossouw, Shabir A. Madhi, Penny L. Moore, Simone I. Richardson
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
The kinetics of Fc-mediated functions following SARS-CoV-2 infection or vaccination in people living with HIV (PLWH) are not known. We compared SARS-CoV-2 spike-specific Fc functions, binding, and neutralization in PLWH and people without HIV (PWOH)
Externí odkaz:
https://doaj.org/article/c33845a85ecd48a4a196b848e6494360
Autor:
Catherine M. Worsley, Mieke A. van der Mescht, Daniel Hoffmann, Pieter W.A. Meyer, Veronica Ueckermann, Theresa M. Rossouw
Publikováno v:
Journal of Infection. 85:334-363
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3b126d6b9f05995a8f9931adcd7b7bf
https://doi.org/10.1016/j.jinf.2022.06.008
https://doi.org/10.1016/j.jinf.2022.06.008
Autor:
Thandeka Moyo-Gwete, Mashudu Madzivhandila, Nonhlanhla N Mkhize, Prudence Kgagudi, Frances Ayres, Bronwen E Lambson, Nelia P Manamela, Simone I Richardson, Zanele Makhado, Mieke A van der Mescht, Zelda de Beer, Talita Roma de Villiers, Wendy A Burgers, Ntobeko A B Ntusi, Theresa Rossouw, Veronica Ueckermann, Michael T Boswell, Penny L Moore
Publikováno v:
Journal of Virology. 96
As SARS-CoV-2 continues to evolve, several variants of concern (VOCs) have arisen which are defined by multiple mutations in their spike proteins. These VOCs have shown variable escape from antibody responses, and have been shown to trigger qualitati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ed5186ecfd03a0afb63e84b7a59f84c
https://doi.org/10.1128/jvi.00558-22
https://doi.org/10.1128/jvi.00558-22
Autor:
Simone I. Richardson, Thopisang Motlou, Mieke A. van der Mescht, Bronwen E. Lambson, Josie Everatt, Daniel Gyamfi Amoako, Anne von Gottberg, Nicole Wolter, Zelda de Beer, Talita Roma de Villiers, Annie Bodenstein, Gretha van den Berg, Theresa M. Rossouw, Michael T. Boswell, Veronica Ueckermann, Jinal N. Bhiman, Penny L. Moore
SARS-CoV-2 variants of concern (VOCs) differentially trigger neutralizing antibodies with variable cross-neutralizing capacity. Here we show that unlike SARS-CoV-2 Omicron BA.1, which triggered neutralizing antibodies with limited cross-reactivity, B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::674e29a39a86baa8fe9ffa7f6903a1ea
https://doi.org/10.1101/2022.07.14.500039
https://doi.org/10.1101/2022.07.14.500039
Autor:
Simone I. Richardson, Prudence Kgagudi, Nelia P. Manamela, Haajira Kaldine, Elizabeth M. Venter, Thanusha Pillay, Bronwen E. Lambson, Mieke A. van der Mescht, Tandile Hermanus, Zelda de Beer, Talita Roma de Villiers, Annie Bodenstein, Gretha van den Berg, Marizane du Pisanie, Wendy A. Burgers, Ntobeko A.B. Ntusi, Veronica Ueckermann, Theresa M. Rossouw, Michael T. Boswell, Penny L. Moore
SummaryThe SARS-CoV-2 Omicron BA.1 variant, which exhibits high level neutralization resistance, has since evolved into several sub-lineages including BA.4 and BA.5, which have dominated the fifth wave of infection in South Africa. Here we assessed t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a07a3b1aeb0550ad002ecbe23c11908
https://doi.org/10.1101/2022.07.14.500042
https://doi.org/10.1101/2022.07.14.500042
Autor:
Simone I. Richardson, Prudence Kgagudi, Nelia P. Manamela, Haajira Kaldine, Elizabeth M. Venter, Thanusha Pillay, Bronwen E. Lambson, Mieke A. van der Mescht, Tandile Hermanus, Sashkia R. Balla, Zelda de Beer, Talita R. de Villiers, Annie Bodenstein, Gretha van den Berg, Marizane du Pisanie, Wendy A. Burgers, Ntobeko A.B. Ntusi, Fareed Abdullah, Veronica Ueckermann, Theresa M. Rossouw, Michael T. Boswell, Penny L. Moore
Publikováno v:
Cell reports. Medicine.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.4 and BA.5 variants caused major waves of infections. Here, we assess the sensitivity of BA.4 to binding, neutralization, and antibody-dependent cellular cytotoxicity (ADCC)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96f019d8617a2f5715523b97216f694e
https://pubmed.ncbi.nlm.nih.gov/36603577
https://pubmed.ncbi.nlm.nih.gov/36603577
Autor:
Dale Kitchin, Simone I. Richardson, Mieke A. van der Mescht, Thopisang Motlou, Nonkululeko Mzindle, Thandeka Moyo-Gwete, Zanele Makhado, Frances Ayres, Nelia P. Manamela, Holly Spencer, Bronwen Lambson, Brent Oosthuysen, Haajira Kaldine, Marizane du Pisanie, Mathilda Mennen, Sango Skelem, Noleen Williams, Ntobeko A.B. Ntusi, Wendy A. Burgers, Glenda G. Gray, Linda-Gail Bekker, Michael T. Boswell, Theresa M. Rossouw, Veronica Ueckermann, Penny L. Moore
Publikováno v:
Cell reports. Medicine. 3(3)
The Janssen (JohnsonJohnson) Ad26.COV2.S non-replicating viral vector vaccine has been widely deployed for COVID-19 vaccination programs in resource-limited settings. Here we confirm that neutralizing and binding antibody responses to Ad26.COV2.S vac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4c4830fc9f6d85103b3222da8a00ef6
https://pubmed.ncbi.nlm.nih.gov/35474738
https://pubmed.ncbi.nlm.nih.gov/35474738
Autor:
Sango Skelem, Frances Ayres, Noleen Williams, Dale Kitchin, Holly Spencer, Mathilda Mennen, Bronwen E. Lambson, Glenda G Gray, Ntobeko A B Ntusi, Mieke A van der Mescht, Thandeka Moyo-Gwete, Linda-Gail Bekker, Veronica Ueckermann, Brent Oosthuysen, Michael T. Boswell, Thopisang Motlou, Nelia P. Manamela, Simone I. Richardson, Theresa M. Rossouw, Nonkululeko Mzindle, Zanele Makhado, Wendy A. Burgers, Penelope L. Moore
The Janssen (Johnson & Johnson) Ad26.COV2.S non-replicating viral vector vaccine has been widely deployed for COVID-19 vaccination programs in resource-limited settings. Here we confirm that neutralizing and binding responses to Ad26.COV2.S vaccinati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d25118eb60231811f363a9f339f0d0e0
https://doi.org/10.1101/2021.11.08.21266049
https://doi.org/10.1101/2021.11.08.21266049